Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remetinostat - Medivir AB

Next Previous
X
Search
Drug Profile

Remetinostat - Medivir AB

Alternative Names: Remetinostat gel 1%; SHAPE; SHP-141; SHP-141C; Suberohydroxamic acid phenyl ester

Latest Information Update: 29 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard University
  • Developer Medivir AB; Shape Pharmaceuticals; Stanford University School of Medicine
  • Class Antineoplastics; Antipsoriatics; Benzoic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Basal cell cancer; Cutaneous T-cell lymphoma

Highest Development Phases

  • Phase II Basal cell cancer; Cutaneous T-cell lymphoma; Squamous cell cancer
  • Discontinued Plaque psoriasis

Most Recent Events

  • 18 Nov 2021 Updated efficacy data from a phase II trial in Squamous cell cancer was released by Medivir
  • 16 Aug 2021 Medivir AB restructures agreement with TetraLogic Pharmaceuticals Corporation and The Leukemia & Lymphoma Society for remetinostat in the treatment of cutaneous T-cell lymphoma and other types of skin cancers
  • 12 Aug 2021 Efficacy and safety data from phase II trial in Basal cell cancer released by Medivir

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top